The sedative propofol reduced the proliferation of BGC823 and GES-1 gastric cancer cells by significantly decreasing the expression of both AKR1B1 and AKR1B10 via the NRF2-mediated polyol pathway. Here, AKR1B10 is linked to gastric cancer.